Firms unite to develop antibiotics against drug-resistant bacteria

09/12/2013 | Pharmaceutical Business Review Online

Swiss firm Debiopharm Group and TCG Lifesciences, a contract research services company, agreed to jointly develop antibiotics against drug-resistant bacteria. Debiopharm will fund the collaboration and share its drug development expertise. TCG's "extensive experience in medicinal chemistry and infectious diseases is a major asset for the development of Debio 1348," Debiopharm President Rolland-Yves Mauvernay said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC